Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

Open in Screener

ELVN

Enliven Therapeutics Inc

Jan 22 • 04:00PM ET

27.03

-0.17 -0.64 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX ALNY IONS BMRN INCY NBIX PRTA EXEL ONC

| Held by: IWM VTI IWO IBB VXF SCHA XPH IHE VTWO IWC

Index	RUT	P/E	-	EPS (ttm)	-1.85	Insider Own	26.77%	Shs Outstand	59.26M	Perf Week	3.76%
Market Cap	1.60B	Forward P/E	-	EPS next Y	-2.02	Insider Trans	-2.31%	Shs Float	43.46M	Perf Month	60.23%
Enterprise Value	1.13B	PEG	-	EPS next Q	-0.38	Inst Own	78.35%	Short Float	19.13%	Perf Quarter	27.56%
Income	-97.21M	P/S	-	EPS this Y	8.68%	Inst Trans	1.22%	Short Ratio	8.62	Perf Half Y	20.94%
Sales	0.00M	P/B	3.36	EPS next Y	-17.21%	ROA	-24.41%	Short Interest	8.31M	Perf YTD	75.52%
Book/sh	8.03	P/C	3.36	EPS next 5Y	-15.94%	ROE	-25.43%	52W High	29.98 -9.84%	Perf Year	22.86%
Cash/sh	8.05	P/FCF	-	EPS past 3/5Y	43.93% 19.02%	ROIC	-20.42%	52W Low	13.30 103.23%	Perf 3Y	60.89%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.61% 9.95%	Perf 5Y	-51.17%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	3.18%	Oper. Margin	-	ATR (14)	2.04	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	32.95	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	71.47	Recom	1.10
Dividend Gr. 3/5Y	- -	Current Ratio	32.95	EPS Q/Q	32.35%	SMA20	29.62%	Beta	0.32	Target Price	40.78
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	32.98%	Rel Volume	1.55	Prev Close	27.20
Employees	62	LT Debt/Eq	0.00	Earnings	Nov 12 AMC	SMA200	35.76%	Avg Volume	964.27K	Price	27.03
IPO	Mar 12, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	26.15% -	Trades		Volume	1,466,783	Change	-0.64%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-16-25	Initiated	Goldman	Buy	$37
Dec-13-24	Initiated	BTIG Research	Buy	$42
Sep-09-24	Initiated	H.C. Wainwright	Buy	$37
Jun-11-24	Initiated	Robert W. Baird	Outperform	$32
Apr-09-24	Initiated	Mizuho	Buy	$34
Mar-29-23	Initiated	Jefferies	Buy	$27

Jan-08-26 02:16PM	Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars (Benzinga) +50.29%
09:00AM	Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones (PR Newswire)
Jan-07-26 09:00AM	Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development (PR Newswire)
Dec-11-25 04:21PM	Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules (PR Newswire) -6.94% -10.18%
09:00AM	Enliven Therapeutics Announces New CEO to Drive Next Phase of Development (PR Newswire)
09:55AM	Loading…
Dec-03-25 09:55AM	Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade (Zacks)
Nov-17-25 09:55AM	Does Enliven Therapeutics, Inc. (ELVN) Have the Potential to Rally 87.49% as Wall Street Analysts Expect? (Zacks)
Nov-12-25 04:05PM	Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update (PR Newswire)
Sep-12-25 09:55AM	Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's What You Should Know (Zacks)
Sep-09-25 12:00PM	Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-27-25 09:55AM	How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41% (Zacks)
Aug-25-25 06:20PM	Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting (PR Newswire)
Aug-13-25 04:05PM	Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update (PR Newswire) +5.80%
Jul-18-25 09:55AM	Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect? (Zacks)
Jun-17-25 01:33PM	Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data (Insider Monkey) -5.59%
04:05PM	Loading…
Jun-16-25 04:05PM	Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire) +5.39%
Jun-13-25 09:30AM	Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire) +11.44%
06:10AM	Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire)
06:02AM	Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress (PR Newswire)
May-22-25 04:05PM	Enliven Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
May-17-25 12:40PM	Enliven price target lowered to $27 from $36 at JonesResearch (TipRanks)
May-14-25 04:05PM	Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update (PR Newswire) -10.41%
09:56AM	Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress (PR Newswire)
Apr-22-25 02:54PM	Enliven Therapeutics: Awaiting Additional Trial Data (Seeking Alpha) +10.79%
Apr-02-25 04:03PM	Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting (PR Newswire) +5.19%
Mar-13-25 04:05PM	Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (PR Newswire)
Feb-25-25 04:05PM	Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (PR Newswire) -5.71%
Jan-31-25 07:00AM	Biotech walks a 'tightrope' amid unclear funding, regulations (Yahoo Finance Video)
Nov-13-24 04:05PM	Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update (PR Newswire) -5.04%
Nov-07-24 04:05PM	Enliven Therapeutics to Present at the Jefferies London Healthcare Conference (PR Newswire)
04:38PM	Loading…
Oct-18-24 04:38PM	Why this largely unknown company is one analyst's top biotech pick (Yahoo Finance Video)
Oct-04-24 09:00AM	FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket (PR Newswire) +7.92%
Sep-30-24 04:52AM	Enliven Therapeutics ELVN-001 shows promise in Phase I CML trial (Clinical Trials Arena) +5.84%
Sep-28-24 09:35AM	Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia (GlobeNewswire)
Sep-26-24 08:50AM	Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going (Zacks)
Sep-18-24 04:05PM	Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML (GlobeNewswire) +6.02%
Sep-09-24 02:05PM	Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst (Benzinga) +7.28%
Sep-04-24 09:55AM	Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High? (Zacks)
Aug-16-24 09:55AM	Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet (Zacks)
Aug-13-24 04:05PM	Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update (GlobeNewswire)
May-29-24 04:05PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) -8.14% +5.67%
May-20-24 05:06PM	Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing (MT Newswires)
May-14-24 10:54PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
05:01PM	Enliven Therapeutics Q1 Loss Narrows (MT Newswires)
04:05PM	Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update (GlobeNewswire)
Apr-19-24 03:03PM	MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-11-24 03:44PM	Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program (Benzinga) +20.18%
07:55AM	Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia (GlobeNewswire)
Apr-09-24 04:05PM	Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors (GlobeNewswire)
Mar-28-24 04:05PM	Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024 (GlobeNewswire) -5.58% +7.45%
Mar-23-24 01:51AM	Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares (GuruFocus.com)
Mar-19-24 08:30AM	Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates (GlobeNewswire) +38.77%
Mar-14-24 09:53PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -5.95%
04:05PM	Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-27-24 04:05PM	Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Jan-03-24 09:01AM	Enliven Therapeutics Inc CFO Benjamin Hohl Sells 11,870 Shares (GuruFocus.com)
Nov-09-23 04:05PM	Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) -7.97%
Aug-17-23 06:40AM	7 A-Rated Biotech Stocks for Your August Buy List (InvestorPlace) +6.00%
Aug-10-23 04:05PM	Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-31-23 04:55PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) +8.85%
May-11-23 04:05PM	Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Mar-24-23 06:30AM	7 Biotech Stocks Sitting in the Sweet Spot (InvestorPlace)

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jan 20 '26	Sale	26.75	20,000	535,099	745,188	Jan 22 05:34 PM
Heyman Richard A.	Director	Jan 20 '26	Sale	26.75	1,230	32,902	23,877	Jan 22 05:33 PM
Heyman Richard A.	Director	Jan 20 '26	Proposed Sale	26.71	1,230	32,853		Jan 20 04:55 PM
Patel Anish	CHIEF OPERATING OFFICER	Jan 09 '26	Sale	27.99	48,300	1,351,762	215,011	Jan 13 05:54 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jan 09 '26	Sale	27.22	91,198	2,482,578	765,188	Jan 12 05:12 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jan 08 '26	Sale	24.05	41,302	993,436	856,386	Jan 12 05:12 PM
Heyman Richard A.	Director	Jan 08 '26	Sale	25.03	9,635	241,156	25,545	Jan 12 05:11 PM
Heyman Richard A.	Director	Jan 09 '26	Sale	25.00	4,285	107,125	25,107	Jan 12 05:11 PM
Lyssikatos Joseph P	Officer	Jan 09 '26	Proposed Sale	23.25	75,000	1,743,750		Jan 09 04:50 PM
Kintz Samuel	Officer	Jan 09 '26	Proposed Sale	23.25	75,000	1,743,750		Jan 09 04:49 PM
Patel Anish	Officer	Jan 09 '26	Proposed Sale	23.25	48,300	1,122,975		Jan 09 04:18 PM
Kintz Samuel	Officer	Jan 08 '26	Proposed Sale	15.47	82,500	1,276,275		Jan 08 04:42 PM
Lyssikatos Joseph P	Officer	Jan 08 '26	Proposed Sale	15.47	82,500	1,276,275		Jan 08 04:26 PM
Heyman Richard A.	Director	Jan 08 '26	Proposed Sale	15.47	1,620	25,061		Jan 08 04:26 PM
Heyman Richard A.	Director	Jan 08 '26	Proposed Sale	15.47	12,300	190,281		Jan 08 04:18 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Dec 22 '25	Option Exercise	2.48	13,000	32,240	36,000	Dec 23 06:47 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Dec 19 '25	Sale	16.84	5,000	84,206	897,688	Dec 23 06:45 PM
Kunkel Lori Anne	Director	Dec 17 '25	Option Exercise	1.12	15,958	17,873	30,712	Dec 19 05:58 PM
Lyssikatos Joseph P	Officer	Dec 19 '25	Proposed Sale	16.68	5,000	83,400		Dec 19 04:32 PM
Kintz Samuel	Officer	Dec 17 '25	Proposed Sale	16.91	5,000	84,550		Dec 17 04:23 PM
Patel Anish	CHIEF OPERATING OFFICER	Dec 08 '25	Sale	21.02	6,663	140,073	263,311	Dec 10 05:13 PM
Patel Anish	Officer	Dec 08 '25	Proposed Sale	21.81	6,663	145,320		Dec 08 04:18 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Nov 19 '25	Sale	22.33	12,500	279,155	902,688	Nov 21 05:28 PM
Kintz Samuel	PRESIDENT AND CEO	Nov 17 '25	Sale	21.82	12,500	272,739	890,392	Nov 19 06:45 PM
Lyssikatos Joseph P	Officer	Nov 19 '25	Proposed Sale	22.59	12,500	282,375		Nov 19 04:05 PM
Kintz Samuel	Officer	Nov 17 '25	Proposed Sale	22.07	12,500	275,875		Nov 17 04:16 PM
Patel Anish	CHIEF OPERATING OFFICER	Nov 07 '25	Sale	17.40	6,667	116,034	269,974	Nov 12 05:34 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 20 '25	Sale	22.08	12,500	276,025	915,188	Oct 22 07:20 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 17 '25	Sale	21.33	12,500	266,654	902,892	Oct 21 06:13 PM
Lyssikatos Joseph P	Officer	Oct 20 '25	Proposed Sale	21.41	12,500	267,625		Oct 20 04:10 PM
Kintz Samuel	Officer	Oct 17 '25	Proposed Sale	21.75	12,500	271,875		Oct 17 04:16 PM
Patel Anish	CHIEF OPERATING OFFICER	Oct 07 '25	Sale	20.10	6,667	133,993	276,641	Oct 09 05:21 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sep 29 '25	Option Exercise	2.48	3,250	8,060	26,250	Oct 01 04:46 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sep 29 '25	Sale	20.40	3,250	66,291	23,000	Oct 01 04:46 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Sep 26 '25	Sale	20.25	4,000	81,005	927,688	Sep 30 05:53 PM
Kintz Samuel	PRESIDENT AND CEO	Sep 26 '25	Sale	20.06	3,700	74,228	915,392	Sep 30 05:51 PM
Hohl Benjamin	Officer	Sep 29 '25	Proposed Sale	20.01	4,500	90,045		Sep 29 05:19 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Sep 23 '25	Sale	20.03	1,500	30,045	931,688	Sep 25 07:44 PM
Kintz Samuel	PRESIDENT AND CEO	Sep 23 '25	Sale	20.03	2,800	56,084	919,092	Sep 25 07:42 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Sep 19 '25	Sale	19.39	7,000	135,697	933,188	Sep 23 05:14 PM
Kintz Samuel	PRESIDENT AND CEO	Sep 17 '25	Sale	19.09	5,000	95,473	922,892	Sep 19 07:12 PM
Kintz Samuel	PRESIDENT AND CEO	Sep 19 '25	Sale	20.25	1,000	20,250	921,892	Sep 19 07:12 PM
Lyssikatos Joseph P	Officer	Sep 19 '25	Proposed Sale	19.93	12,500	249,125		Sep 19 05:32 PM
Kintz Samuel	Officer	Sep 17 '25	Proposed Sale	18.43	12,500	230,375		Sep 17 04:08 PM
Patel Anish	CHIEF OPERATING OFFICER	Sep 08 '25	Sale	20.24	6,667	134,957	283,308	Sep 10 08:12 PM
Patel Anish	Officer	Sep 08 '25	Proposed Sale	20.15	20,001	403,020		Sep 08 04:30 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Aug 27 '25	Option Exercise	2.48	3,250	8,060	26,250	Aug 29 05:03 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Aug 27 '25	Sale	20.63	3,250	67,039	23,000	Aug 29 05:03 PM
Hohl Benjamin	Officer	Aug 27 '25	Proposed Sale	20.32	5,250	106,680		Aug 27 04:44 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Aug 21 '25	Sale	20.01	7,500	150,099	940,188	Aug 21 06:46 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Aug 19 '25	Sale	19.62	5,000	98,118	947,688	Aug 21 06:46 PM
Kintz Samuel	PRESIDENT AND CEO	Aug 18 '25	Sale	20.02	10,393	208,106	929,999	Aug 20 04:36 PM
Kintz Samuel	PRESIDENT AND CEO	Aug 19 '25	Sale	20.00	590	11,800	929,409	Aug 20 04:36 PM
Lyssikatos Joseph P	Officer	Aug 19 '25	Proposed Sale	19.75	12,500	246,875		Aug 19 04:24 PM
Kintz Samuel	Officer	Aug 18 '25	Proposed Sale	20.22	12,500	252,750		Aug 18 04:21 PM
Patel Anish	CHIEF OPERATING OFFICER	Aug 07 '25	Sale	18.24	6,667	121,616	289,975	Aug 11 06:51 PM
Patel Anish	Officer	Aug 07 '25	Proposed Sale	18.84	6,667	125,606		Aug 07 04:19 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 28 '25	Option Exercise	2.48	3,250	8,060	26,250	Jul 30 05:57 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 28 '25	Sale	20.46	3,250	66,504	23,000	Jul 30 05:57 PM
Hohl Benjamin	Officer	Jul 28 '25	Proposed Sale	21.20	4,250	90,100		Jul 28 04:09 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jul 21 '25	Sale	22.29	12,500	278,646	952,688	Jul 23 06:52 PM
Kintz Samuel	PRESIDENT AND CEO	Jul 17 '25	Sale	22.52	12,500	281,518	940,392	Jul 21 07:21 PM
Lyssikatos Joseph P	Officer	Jul 21 '25	Proposed Sale	22.66	12,500	283,250		Jul 21 04:10 PM
Kintz Samuel	Officer	Jul 17 '25	Proposed Sale	21.46	12,500	268,250		Jul 17 04:13 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 10 '25	Option Exercise	2.48	1,000	2,480	24,000	Jul 14 05:07 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 10 '25	Sale	22.66	1,000	22,655	23,000	Jul 14 05:07 PM
Patel Anish	CHIEF OPERATING OFFICER	Jul 07 '25	Sale	19.79	6,667	131,951	296,642	Jul 09 07:29 PM
Patel Anish	Officer	Jul 07 '25	Proposed Sale	20.73	6,667	138,207		Jul 07 04:15 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 27 '25	Option Exercise	2.48	3,250	8,060	26,250	Jul 01 04:42 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 27 '25	Sale	20.91	3,250	67,956	23,000	Jul 01 04:42 PM
Hohl Benjamin	Officer	Jun 27 '25	Proposed Sale	21.52	4,250	91,460		Jun 27 04:01 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jun 20 '25	Sale	21.40	12,500	267,458	965,188	Jun 24 05:36 PM
Lyssikatos Joseph P	Officer	Jun 20 '25	Proposed Sale	21.57	12,500	269,625		Jun 20 04:02 PM
Kintz Samuel	PRESIDENT AND CEO	Jun 17 '25	Sale	22.18	12,500	277,292	952,892	Jun 18 06:22 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 13 '25	Option Exercise	2.48	3,000	7,440	26,000	Jun 17 04:24 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 13 '25	Sale	22.55	3,000	67,655	23,000	Jun 17 04:24 PM
Kintz Samuel	Officer	Jun 17 '25	Proposed Sale	23.09	12,500	288,625		Jun 17 04:15 PM
Hohl Benjamin	Officer	Jun 13 '25	Proposed Sale	19.99	3,000	59,980		Jun 13 04:08 PM
Patel Anish	CHIEF OPERATING OFFICER	Jun 09 '25	Sale	20.34	6,667	135,574	303,309	Jun 11 06:25 PM
Patel Anish	Officer	Jun 09 '25	Proposed Sale	20.74	6,667	138,274		Jun 09 04:21 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jun 03 '25	Sale	20.03	7,500	150,220	977,688	Jun 05 04:55 PM
Kintz Samuel	PRESIDENT AND CEO	Jun 03 '25	Sale	20.05	7,500	150,352	965,392	Jun 05 04:53 PM
Kintz Samuel	Officer	Jun 03 '25	Proposed Sale	19.14	7,500	143,550		Jun 03 05:34 PM
Lyssikatos Joseph P	Officer	Jun 03 '25	Proposed Sale	19.14	7,500	143,550		Jun 03 05:14 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	May 27 '25	Option Exercise	2.48	3,250	8,060	26,250	May 29 05:38 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	May 27 '25	Sale	16.18	3,250	52,593	23,000	May 29 05:38 PM
Hohl Benjamin	Officer	May 27 '25	Proposed Sale	16.40	3,250	53,300		May 27 04:03 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	May 19 '25	Sale	16.31	5,000	81,534	985,188	May 21 06:31 PM
Kintz Samuel	PRESIDENT AND CEO	May 19 '25	Sale	16.49	5,000	82,453	972,892	May 21 06:29 PM
Kintz Samuel	Officer	May 19 '25	Proposed Sale	16.86	5,000	84,300		May 19 04:22 PM
Lyssikatos Joseph P	Officer	May 19 '25	Proposed Sale	16.86	5,000	84,300		May 19 04:21 PM
Patel Anish	CHIEF OPERATING OFFICER	May 07 '25	Sale	18.39	6,667	122,579	309,976	May 09 06:48 PM
Patel Anish	Officer	May 07 '25	Proposed Sale	19.69	6,667	131,273		May 07 04:11 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	May 01 '25	Sale	20.07	5,030	100,966	992,658	May 05 06:43 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	May 02 '25	Sale	20.01	2,470	49,424	990,188	May 05 06:43 PM
Kintz Samuel	PRESIDENT AND CEO	May 01 '25	Sale	20.08	5,330	107,007	980,062	May 05 06:42 PM
Kintz Samuel	PRESIDENT AND CEO	May 02 '25	Sale	20.00	2,170	43,409	977,892	May 05 06:42 PM
Lyssikatos Joseph P	Officer	May 01 '25	Proposed Sale	18.94	7,500	142,050		May 01 04:03 PM
Kintz Samuel	Officer	May 01 '25	Proposed Sale	18.94	7,500	142,050		May 01 04:02 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Apr 28 '25	Option Exercise	2.48	3,250	8,060	26,250	Apr 30 06:59 PM

Open in Screener

ORIC

ORIC Pharmaceuticals Inc

Jan 22 • 04:00PM ET

12.05

-0.20 -1.63 %

Healthcare • Biotechnology • USA • NASD

ORIC ORIC Pharmaceuticals Inc daily Stock Chart

Peers: PFE MRK BMY GILD ABBV AMGN LLY VRTX REGN BIIB

| Held by: XBI IWM VTI VXF IWN IBB SCHA VTWO DFAS IWC

Index	RUT	P/E	-	EPS (ttm)	-1.73	Insider Own	44.38%	Shs Outstand	97.28M	Perf Week	7.11%
Market Cap	1.17B	Forward P/E	-	EPS next Y	-1.59	Insider Trans	-0.74%	Shs Float	54.17M	Perf Month	49.88%
Enterprise Value	889.70M	PEG	-	EPS next Q	-0.37	Inst Own	66.60%	Short Float	39.63%	Perf Quarter	-4.37%
Income	-135.27M	P/S	-	EPS this Y	11.55%	Inst Trans	8.38%	Short Ratio	15.18	Perf Half Y	2.12%
Sales	0.00M	P/B	2.88	EPS next Y	1.76%	ROA	-36.90%	Short Interest	21.47M	Perf YTD	47.31%
Book/sh	4.18	P/C	4.09	EPS next 5Y	3.94%	ROE	-39.73%	52W High	14.93 -19.29%	Perf Year	20.50%
Cash/sh	2.95	P/FCF	-	EPS past 3/5Y	4.02% -15.32%	ROIC	-33.24%	52W Low	3.90 209.36%	Perf 3Y	105.63%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.08% 6.80%	Perf 5Y	-64.03%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	4.29%	Oper. Margin	-	ATR (14)	0.73	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	14.65	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	69.36	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	14.65	EPS Q/Q	32.80%	SMA20	26.64%	Beta	1.33	Target Price	21.00
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	17.17%	Rel Volume	0.83	Prev Close	12.25
Employees	115	LT Debt/Eq	0.00	Earnings	Nov 13 AMC	SMA200	23.87%	Avg Volume	1.41M	Price	12.05
IPO	Apr 24, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	18.56% -	Trades		Volume	1,180,686	Change	-1.63%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Initiated	Piper Sandler	Overweight	$22
Nov-20-25	Initiated	Evercore ISI	Outperform	$25
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Sep-04-25	Resumed	Guggenheim	Buy	$18
Jul-08-25	Initiated	Ladenburg Thalmann	Buy	$15
Oct-31-24	Initiated	Wells Fargo	Overweight	$20
Sep-06-24	Initiated	Stifel	Buy	$20
Feb-23-24	Initiated	Cantor Fitzgerald	Overweight
Sep-22-23	Initiated	Wedbush	Outperform	$8
Mar-23-23	Upgrade	H.C. Wainwright	Neutral → Buy	$16
Mar-21-23	Upgrade	Guggenheim	Neutral → Buy	$15
Mar-16-23	Upgrade	Oppenheimer	Perform → Outperform	$14
Jul-18-22	Resumed	Oppenheimer	Perform
Apr-04-22	Upgrade	Citigroup	Neutral → Buy	$7 → $10
Mar-25-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-22-22	Downgrade	Oppenheimer	Outperform → Perform
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Mar-22-22	Downgrade	Citigroup	Buy → Neutral	$22 → $7
Jul-06-21	Upgrade	Citigroup	Neutral → Buy	$34
Jan-25-21	Downgrade	Citigroup	Buy → Neutral	$34

Show Previous Ratings

Jan-21-26 05:59AM	Piper Sandler Puts its Weight Behind 2 Strong Buy Cancer Stocks (TipRanks) +5.42%
Jan-15-26 01:23PM	Oric Pharmaceuticals Stock Sees Healthy RS Rating Jump To 80 (Investor's Business Daily)
Jan-14-26 10:52AM	Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff (PR Newswire) +10.95%
Jan-12-26 08:30AM	ORIC Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones (GlobeNewswire)
Jan-06-26 04:05PM	ORIC Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.63%
11:11PM	Loading…
Dec-15-25 11:11PM	ORIC Pharmaceuticals (ORIC) Surges as Intriguing ESMO Asia Data for Enozertinib Prompts Wells Fargo to Assign Higher Value (Insider Monkey)
Dec-05-25 08:00PM	ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025 (GlobeNewswire)
04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:00AM	ORIC Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025 (GlobeNewswire)
Dec-04-25 09:45PM	ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025 (GlobeNewswire)
Dec-03-25 04:01PM	ORIC Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025 (GlobeNewswire)
Dec-01-25 08:00AM	ORIC Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025 (GlobeNewswire) -6.14%
Nov-24-25 04:05PM	ORIC Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-18-25 12:00PM	Oric Pharmaceuticals (ORIC) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-13-25 04:10PM	ORIC Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates (GlobeNewswire)
04:05PM	Loading…
04:05PM	ORIC Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety (GlobeNewswire)
Nov-07-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 04:00PM	ORIC Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor (GlobeNewswire)
Nov-04-25 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-27-25 08:30AM	ORIC Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors (GlobeNewswire)
Oct-22-25 09:24AM	BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now? (Zacks)
Sep-17-25 01:45PM	Oric Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Sep-05-25 04:05PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-27-25 04:05PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 04:05PM	ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer (GlobeNewswire)
Aug-12-25 04:05PM	ORIC Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates (GlobeNewswire)
Aug-01-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-15-25 09:55AM	Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Jul-11-25 12:00PM	Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy? (Zacks)
Jul-03-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
12:00PM	Loading…
Jun-19-25 12:00PM	All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy (Zacks)
09:55AM	Does Oric Pharmaceuticals (ORIC) Have the Potential to Rally 104.99% as Wall Street Analysts Expect? (Zacks)
Jun-13-25 12:00PM	What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now? (Zacks)
11:30AM	JPMorgan biotech/pharma analysts hold analyst/industry conference call (TipRanks)
Jun-06-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.79%
Jun-02-25 09:55AM	Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know (Zacks)
May-29-25 11:53AM	ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study (Zacks) +33.50%
12:09AM	ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials (Insider Monkey)
May-28-25 04:05PM	ORIC Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC (GlobeNewswire)
04:05PM	ORIC Pharmaceuticals Announces $125 Million Private Placement Financing (GlobeNewswire)
May-27-25 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -8.98%
08:00AM	ORIC Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC (GlobeNewswire)
May-05-25 04:05PM	ORIC Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates (GlobeNewswire) -11.58%
May-02-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-28-25 04:30PM	ORIC Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +11.10%
Apr-22-25 09:15AM	ORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch Biotech (Seeking Alpha) +7.19%
07:30AM	ORIC Pharmaceuticals: Looking To The Horizon With Pivotal Study Plans (Seeking Alpha)
Apr-16-25 11:09AM	Is ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey) -6.94%
Apr-04-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.22% -5.94%
Mar-31-25 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.12%
Mar-25-25 04:30PM	ORIC Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -8.41% -13.33%
Mar-07-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-25-25 04:15PM	ORIC Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones (GlobeNewswire) +6.88%
Feb-18-25 04:05PM	ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates (GlobeNewswire) -6.10%
Feb-07-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.33%
Jan-27-25 04:15PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.85%
Jan-15-25 10:10AM	Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year (PR Newswire) +9.69%
Jan-14-25 08:35AM	Oric Pharmaceuticals announces clinical supply agreement with Janssen (TipRanks) +15.23%
Jan-13-25 08:05AM	ORIC Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones (GlobeNewswire) +8.04%
08:00AM	ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations (GlobeNewswire)
Jan-06-25 04:15PM	ORIC Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.82%
Jan-03-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-25-24 04:15PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 04:05PM	ORIC Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates (GlobeNewswire)
Nov-04-24 04:15PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-01-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-23-24 07:00AM	ORIC Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-09-24 04:15PM	ORIC Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-04-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-17-24 12:00PM	OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration (PR Newswire)
Sep-14-24 05:35PM	ORIC Pharmaceuticals, Inc. (ORIC): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Sep-06-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-26-24 04:05PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.04%
Aug-12-24 04:05PM	ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates (GlobeNewswire) +6.76%
Aug-05-24 04:15PM	ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs (GlobeNewswire) -8.65%
Aug-02-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.48%
Jul-17-24 11:20AM	ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ (Zacks) -7.01%
Jul-16-24 04:59PM	ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer (GlobeNewswire)
Jul-09-24 07:30AM	Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors (GlobeNewswire) +9.88%
Jul-08-24 06:00PM	Why Is ORIC Pharmaceuticals, Inc. (ORIC) Among the Most Shorted Stocks That Are Loved by Analysts? (Insider Monkey) +10.53%
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jul-05-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-07-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-24 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.68%
May-06-24 09:54PM	ORIC Stock Earnings: ORIC Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates (GlobeNewswire)
May-03-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-15-24 04:15PM	ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC (GlobeNewswire)
Apr-08-24 08:00AM	ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Apr-05-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-04-24 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-26-24 09:55AM	How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3% (Zacks)
Mar-12-24 09:01PM	ORIC Pharmaceuticals Inc (ORIC) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com) +6.35%
Mar-11-24 04:05PM	ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates (GlobeNewswire)
Mar-08-24 05:01PM	ORIC Pharmaceuticals Inc CEO Jacob Chacko Sells 40,000 Shares (GuruFocus.com) -5.78%
Mar-06-24 04:30PM	ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Mar-05-24 04:30PM	ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-01-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.07%
Feb-14-24 04:30PM	ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit (GlobeNewswire)
Feb-09-24 02:23AM	ORIC Pharmaceuticals CEO Jacob Chacko Sells 40,000 Shares (GuruFocus.com)

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heyman Richard A.	Director	Jan 16 '26	Sale	12.00	3,500	42,016	41,800	Jan 20 07:19 PM
Heyman Richard A.	Director	Jan 16 '26	Sale	12.00	3,200	38,415	213,072	Jan 20 07:19 PM
Richard A, Heyman	Director	Jan 16 '26	Proposed Sale	12.00	6,400	76,800		Jan 16 04:57 PM
Richard A, Heyman	Director	Jan 16 '26	Proposed Sale	12.00	7,000	84,000		Jan 16 04:43 PM
Multani Pratik S	Chief Medical Officer	Dec 15 '25	Option Exercise	0.00	29,333	0	78,869	Dec 17 07:21 PM
Multani Pratik S	Chief Medical Officer	Dec 16 '25	Sale	9.06	10,720	97,129	68,149	Dec 17 07:21 PM
Piscitelli Dominic	Chief Financial Officer	Dec 15 '25	Option Exercise	0.00	29,333	0	78,868	Dec 17 07:19 PM
Piscitelli Dominic	Chief Financial Officer	Dec 16 '25	Sale	9.06	10,720	97,127	68,148	Dec 17 07:19 PM
Chacko Jacob	PRESIDENT AND CEO	Dec 15 '25	Option Exercise	0.00	83,666	0	615,085	Dec 17 07:18 PM
Chacko Jacob	PRESIDENT AND CEO	Dec 16 '25	Sale	9.06	33,374	302,368	581,711	Dec 17 07:18 PM
Piscitelli Dominic	Officer	Dec 16 '25	Proposed Sale	9.06	10,720	97,128		Dec 16 09:46 PM
Multani Pratik S	Officer	Dec 16 '25	Proposed Sale	9.06	10,720	97,129		Dec 16 09:44 PM
Chacko Jacob	Officer	Dec 16 '25	Proposed Sale	9.06	33,374	302,370		Dec 16 09:42 PM
Kunkel Lori Anne	Director	Dec 08 '25	Option Exercise	7.90	10,000	79,000	84,200	Dec 09 05:35 PM
Kunkel Lori Anne	Director	Dec 04 '25	Option Exercise	3.75	5,534	20,752	74,200	Dec 05 05:47 PM
Piscitelli Dominic	Chief Financial Officer	Oct 06 '25	Option Exercise	4.36	11,000	47,960	59,317	Oct 08 05:37 PM
Piscitelli Dominic	Chief Financial Officer	Oct 06 '25	Sale	14.52	11,000	159,719	48,317	Oct 08 05:37 PM
Chacko Jacob	PRESIDENT AND CEO	Oct 06 '25	Sale	12.32	37,461	461,520	531,419	Oct 08 05:35 PM
Dominic Piscitelli	Officer	Oct 06 '25	Proposed Sale	14.50	50,000	725,000		Oct 06 04:22 PM
Heyman Richard A.	Director	Oct 03 '25	Option Exercise	1.69	32,800	55,591	45,300	Oct 03 07:18 PM
Chacko Jacob	PRESIDENT AND CEO	Oct 01 '25	Sale	12.05	53,001	638,805	568,880	Oct 02 07:18 PM
Chacko Jacob	PRESIDENT AND CEO	Sep 30 '25	Sale	12.01	34,538	414,750	621,881	Oct 02 07:18 PM
Chacko Jacob	PRESIDENT AND CEO	Sep 22 '25	Sale	10.80	125,000	1,349,938	656,419	Sep 24 04:30 PM
Jacob Chacko	Director	Sep 22 '25	Proposed Sale	10.50	250,000	2,625,000		Sep 22 04:31 PM
Piscitelli Dominic	Chief Financial Officer	Jul 01 '25	Sale	10.05	20,000	200,972	48,317	Jul 02 04:07 PM
Piscitelli Dominic	Chief Financial Officer	Jun 24 '25	Sale	10.50	32,466	341,039	68,317	Jun 24 06:33 PM
Piscitelli Dominic	Chief Financial Officer	Jun 23 '25	Sale	10.00	1,034	10,344	100,783	Jun 24 06:33 PM
You Angie	Director	Jun 20 '25	Buy	9.39	26,597	249,669	26,597	Jun 23 08:05 PM
You Angie	Director	Jun 23 '25	Buy	9.43	1,403	13,230	28,000	Jun 23 08:05 PM
Piscitelli Dominic	Chief Financial Officer	Jun 12 '25	Sale	10.00	300	3,000	101,817	Jun 13 07:38 PM
Piscitelli Dominic	Chief Financial Officer	Jun 11 '25	Sale	10.01	2,976	29,777	102,117	Jun 11 06:37 PM
Piscitelli Dominic	Chief Financial Officer	Jun 10 '25	Sale	10.00	324	3,240	105,093	Jun 11 06:37 PM
Piscitelli Dominic	Chief Financial Officer	Jun 06 '25	Sale	10.01	2,600	26,021	104,164	Jun 09 08:18 PM
Piscitelli Dominic	Chief Financial Officer	Jun 09 '25	Sale	10.00	300	3,000	103,864	Jun 09 08:18 PM
Dominic Piscitelli	Officer	Jun 06 '25	Proposed Sale	9.00	60,000	540,000		Jun 06 04:16 PM
Kunkel Lori Anne	Director	Mar 03 '25	Option Exercise	4.85	48,166	233,512	68,666	Mar 04 05:27 PM

ELVN

Enliven Therapeutics Inc

ORIC

ORIC Pharmaceuticals Inc

Upgrade your FINVIZ experience